US 12,251,467 B2
Vaginal hydrogel for delivery of therapeutics
Marina Lee Gerton, Salt Lake City, UT (US); and Brenda K. Mann, Salt Lake City, UT (US)
Filed by Marina Lee Gerton, Salt Lake City, UT (US); and Brenda K. Mann, Salt Lake City, UT (US)
Filed on Jun. 6, 2023, as Appl. No. 18/330,055.
Application 17/179,854 is a division of application No. 16/233,102, filed on Dec. 27, 2018, granted, now 10,959,945, issued on Mar. 10, 2021.
Application 18/330,055 is a continuation of application No. 17/179,854, filed on Feb. 19, 2021, granted, now 11,701,324.
Claims priority of provisional application 62/645,801, filed on Mar. 21, 2018.
Prior Publication US 2024/0122850 A1, Apr. 18, 2024
Int. Cl. A61K 9/06 (2006.01); A61K 9/00 (2006.01); A61K 9/70 (2006.01); A61K 31/4164 (2006.01); A61K 47/10 (2017.01); A61K 47/32 (2006.01); A61K 47/38 (2006.01); A61P 15/02 (2006.01)
CPC A61K 9/06 (2013.01) [A61K 9/0034 (2013.01); A61K 9/7015 (2013.01); A61K 31/4164 (2013.01); A61K 47/10 (2013.01); A61K 47/32 (2013.01); A61K 47/38 (2013.01); A61P 15/02 (2018.01)] 20 Claims
 
1. A method of vaginally delivering a therapeutic agent, the method comprising vaginally administering to a subject in need thereof, a crosslinked composition comprising:
a modified hyaluronic acid comprising a plurality of thiol groups,
a molecule A comprising at least two thiol-reactive sites,
a mucoadhesive agent, and
the therapeutic agent,
wherein the modified hyaluronic acid is crosslinked to the molecule A at a pH consisting of a value between about 3.2 and about 5.0.